ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO - Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...

BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) BEIJING, China and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...

New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking...

Cisco Systems Investigated by Block & Leviton LLP For Violations of Federal Securities Laws BOSTON, May 13, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating whether Cisco Systems, Inc. (“Cisco” or the “Company”)...

Cisco Announces Streamlined Operating Model SAN JOSE, CA--(Marketwire - May 5, 2011) - Cisco (NASDAQ: CSCO) today announced significant changes to its business structure and operations. The company will streamline its sales, services and...